This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rüsch-Gerdes, S. Articles by Siddiqi, S. Search for Related Content PubMed PubMed Citation Articles by Rüsch-Gerdes, S. Articles by Siddiqi, S.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, March 2006, p. 688-692, Vol. 44, No. 3
0095-1137/06/$08.00+0     doi:10.1128/JCM.44.3.688-692.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer Antimicrobials

National Reference Center for Mycobacteria, Forschungszentrum Borstel, Borstel, Germany,¹ Department of Medical Microbiology, Luzern General Hospital, Lucerne, Switzerland,² Mycobacteria Reference Center, Faculty of Medicine, University of Cordoba, Cordoba, Spain,³ Royal Brompton Hospital, London, United Kingdom,⁴ Becton Dickinson Diagnostic Systems, Sparks, Maryland⁵

Received 5 September 2005/ Returned for modification 28 October 2005/ Accepted 13 December 2005

The BACTEC MGIT 960 system, a fully automated, nonradiometric, noninvasive system for detection and drug susceptibility testing of mycobacteria, was evaluated for the ability to test susceptibilities to second-line drugs. In this study, which was carried out in three phases (phase I, mostly susceptible strains; phase II, mostly resistant strains; phase III, final testing of the optimal drug concentrations found in phases I and II), we established the critical concentrations for seven drugs to be tested in the BACTEC MGIT 960 system compared to the BACTEC 460TB system. The critical concentrations for the seven drugs used in the MGIT 960 system are as follows: amikacin, 1.0 µg/ml; capreomycin, 2.5 µg/ml; ethionamide, 5.0 µg/ml; protionamide, 2.5 µg/ml; ofloxacin, 2.0 µg/ml; rifabutin, 0.5 µg/ml; linezolid, 1.0 µg/ml. Our results demonstrate that the BACTEC MGIT 960 system is an accurate method for rapid testing of the susceptibilities of Mycobacterium tuberculosis to second-line drugs.

This article has been cited by other articles:

• Abe, C., Kobayashi, I., Mitarai, S., Wada, M., Kawabe, Y., Takashima, T., Suzuki, K., Sng, L.-H., Wang, S., Htay, H. H., Ogata, H. (2008). Biological and Molecular Characteristics of Mycobacterium tuberculosis Clinical Isolates with Low-Level Resistance to Isoniazid in Japan. J. Clin. Microbiol. 46: 2263-2268 [Abstract] [Full Text]  
• Shin, S. J., Collins, M. T. (2008). Thiopurine Drugs Azathioprine and 6-Mercaptopurine Inhibit Mycobacterium paratuberculosis Growth In Vitro. Antimicrob. Agents Chemother. 52: 418-426 [Abstract] [Full Text]  
• van Klingeren, B., Dessens-Kroon, M., van der Laan, T., Kremer, K., van Soolingen, D. (2007). Drug Susceptibility Testing of Mycobacterium tuberculosis Complex by Use of a High-Throughput, Reproducible, Absolute Concentration Method. J. Clin. Microbiol. 45: 2662-2668 [Abstract] [Full Text]  
• Wang, J.-Y., Lee, L.-N., Lai, H.-C., Wang, S.-K., Jan, I-S., Yu, C.-J., Hsueh, P.-R., Yang, P.-C. (2007). Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 59: 860-865 [Abstract] [Full Text]  
• Richter, E., Rusch-Gerdes, S., Hillemann, D. (2007). First Linezolid-Resistant Clinical Isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51: 1534-1536 [Abstract] [Full Text]